Trosid

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Trosid

Quick Facts: Trosid

Property Description
Active ingredient Tioconazole
Form Topical solution, Cream, Vaginal suppository
Pharmacological class Azole Antifungal Agent
General purpose To resolve superficial fungal infections (mycoses)
Origin Synthetic drug (Imidazole derivative)

What Type of Medicine is Trosid?

Trosid is a well-established brand name for the medicine based on the active ingredient Tioconazole, classifying it as a synthetic broad-spectrum antifungal agent. The core substance belongs to the imidazole derivative class, placing it within the larger azole antifungal family of antimycotic drugs. This classification reflects that the medicine is specifically designed to target and manage pathogenic fungi. As a single-ingredient product, its action is concentrated on the properties of the Tioconazole molecule, which has the chemical structure C16H13Cl3N2OS.

Composition and Forms of Trosid

The composition of Trosid centers on Tioconazole, delivered in various dosage form(s) suitable for local application, facilitating topical administration or vaginal administration. Common forms include a topical solution (cutaneous solution), often featuring a lipophilic base for penetrating tissues like the nail, and a cream (ointment) with an emulsified base for general skin application. The preparation's different forms allow for localized treatment, particularly the solution formulation, which is often commercially positioned for treating fungal nail infections (onychomycosis).

What is the General Purpose of Trosid?

The general purpose of Trosid is to resolve superficial fungal infections (mycoses) by interfering with the survival structure of the invading organism. This antimycotic action is achieved through a mechanism that impacts the fungal cell membrane integrity. By targeting this fundamental aspect of the pathogen, the drug aids in the management of conditions like athlete's foot (dermatomycoses), a typical scenario for its use. The role of Tioconazole in these infections is to offer a localized therapeutic effect against the growth and proliferation of fungal cells.

What side effects are possible with Trosid?

Possible Side Effects

Trosid (tioconazole) topical solutions and creams are generally well-tolerated following local application. Side effects are typically related to the application site and are usually mild and transient, often appearing within the first week of treatment.

Frequency Common Side Effects (May affect up to 1 in 10 people)
Common Peripheral swelling (e.g., swelling of the hands or feet)
Frequency Uncommon and Other Reported Side Effects (Frequency Not Known)
Uncommon Rash, dermatitis, or skin irritation around the treated area
Not Known Allergic reaction (including symptoms like itching, hives, swelling, or blistering), pain, burning sensation, dry skin, skin peeling, tingling sensations (paraesthesia), nail discoloration, periungual inflammation, and nail pain.

In the event of a severe local reaction or a systemic allergic reaction (such as severe swelling of the face, tongue, or throat, difficulty breathing, or widespread rash), treatment should be discontinued immediately, and emergency medical attention should be sought.


Safety Information and Precautions

Allergies: Do not use Trosid if you have a known hypersensitivity or allergic reaction to tioconazole, any of the excipients, or to other antifungal medicines of the imidazole class.

Pregnancy and Breastfeeding: Consult a healthcare professional before using Trosid if you are pregnant, planning to become pregnant, or breastfeeding. While systemic absorption is considered negligible with topical use, caution is advised. You may be advised to temporarily discontinue breastfeeding during treatment.

Accidental Ingestion: This medication is for external use only. If Trosid is accidentally ingested, seek medical attention immediately. Gastrointestinal symptoms may occur from excessive oral ingestion.

Other Forms: Tioconazole products in the form of vaginal ointments or creams may damage latex condoms and diaphragms, potentially leading to reduced effectiveness of these contraceptives.

Overdose and Emergency Response

Overdose and When to Seek Help

An overdose of Trosid (Clobazam), a benzodiazepine, primarily presents as central nervous system (CNS) depression, with symptoms ranging from mild to severe. Officially documented overdose presentations include drowsiness, confusion, lethargy, and problems with muscle control known as ataxia.

In rare cases, severe overdose can lead to more critical clinical manifestations such as hypotension (low blood pressure), slow, shallow breathing (respiratory depression), and ultimately, coma or death.

Critical Risk Factors

Regulatory authorities specifically warn that the risk of a fatal outcome is significantly increased when Trosid is ingested alongside alcohol or other CNS depressants, including opioids.

When to Seek Immediate Medical Help

Immediate emergency medical attention is required if an overdose is suspected and the patient displays any signs of serious cardio-respiratory compromise, such as slowed or difficult breathing, a decreased urge to breathe, fainting, or unresponsiveness.

Overdose management involves monitoring vital signs and providing supportive care to ensure adequate ventilation. The official management notes indicate that the use of a specific antidote is generally not recommended in patients with epilepsy due to the risk of precipitating seizures.

Therapeutic Uses of Trosid

Trosid, which contains the active ingredient tioconazole, is used in situations involving certain distressing symptoms caused by fungi. Its use is considered relevant in conditions characterized by periods of heightened symptoms caused by various fungi and yeasts.

This active ingredient is commonly used to help manage symptoms related to physical discomfort in conditions presenting with systemic or localized discomfort. Specifically, this medication plays a role in managing symptoms associated with ringworm (tinea corporis), athlete’s foot (tinea pedis), jock itch (tinea cruris), tinea versicolor, and cutaneous candidiasis (skin yeast infections).

These uses are relevant when supportive symptom management is appropriate, such as during phases when symptoms become more noticeable. When applied appropriately, the treatment supports general well-being during symptomatic phases and provides supportive relief when symptoms interfere with routine activities.

Quick Fact: Supports general well-being during symptomatic phases

Eligibility and Restrictions for Use

Who Can and Cannot Use Trosid? — Official Regulatory Information

The eligibility profile for Trosid (Tioconazole) is strictly defined by government regulatory documents, focusing on patient characteristics and infection context.


Eligibility and Contraindications

Classification Population/Condition Regulatory Status
Contraindicated Known hypersensitivity to Tioconazole or other imidazole antifungals. Absolute Prohibition
Contraindicated Pregnant patients (for the Topical Solution/Nail Lacquer formulation only). Absolute Prohibition

Conditional and Restricted Use

Population Group Restriction or Requirement
Children Under 12 Not recommended for self-treatment; must consult a doctor.
Diabetes/Weakened Immunity Self-treatment is not recommended due to risk of complicated or recurrent infection.
Pregnancy/Lactation Use requires consultation with a health professional; use is conditional on benefit outweighing risk (Pregnancy Category C).

Regulatory documents permit use for adults and older adults with no requirement for special precautions or dosage adjustments. Furthermore, self-treatment is prohibited if the patient is experiencing severe symptoms such as fever or abdominal pain, or if the patient has never had a yeast infection diagnosed by a doctor. These rules ensure the medicine is reserved for the officially designated patient populations.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Systemic Drug-Drug Interaction Profile

Trosid, which contains the active ingredient Tioconazole, is formulated exclusively for topical or vaginal administration. Official regulatory documentation confirms that the systemic absorption of the active ingredient is negligible following the recommended use. Consequently, the product is not associated with clinically significant systemic pharmacokinetic interactions with co-administered oral or injectable medicinal products. This lack of systemic exposure means there are no officially documented prohibitions or restrictions related to CYP-mediated metabolic pathways, drug transporters, or pharmacodynamic effects between Trosid and other systemic prescription drugs, as stated in FDA and equivalent regulatory labeling.

Physical Drug-Substance Restrictions

The most critical documented interaction for Trosid involves a physical incompatibility with certain non-medicinal devices. The product's components (such as petrolatum or mineral oil) can compromise the material integrity of products made from latex or rubber, leading to device failure.

Interacting Substance/Device Official Restriction Timing Requirement
Latex Condoms Use Prohibited Must not be used during treatment or for three full days (72 hours) after treatment ends.
Rubber Diaphragms Use Prohibited Must not be used during treatment or for three full days (72 hours) after treatment ends.

This mandatory restriction ensures the continued reliability of these devices for their intended purpose. Furthermore, there are no known interactions documented in official labeling with food, alcohol, or herbal products.

Mechanism of Action

Blocking the Fungal Cell's Structural Factory

This mechanistic domain covers the core fungistatic action of Tioconazole, focusing on its role as an enzyme inhibitor. The drug acts on the Ergosterol Biosynthesis Pathway by inhibiting the fungal enzyme lanosterol 14-alpha demethylase (CYP51). This action blocks the formation of ergosterol, causing structural failure and increased permeability of the fungal cell membrane, which results in the cessation of fungal cell proliferation and growth.

Physical Disruption: The Fungicidal Knockout

This domain describes the rapid, fungicidal component of the mechanism. At high local concentrations, Tioconazole bypasses the enzymatic pathway block and causes direct physical disruption of the fungal cell membrane's lipid bilayer. This acute action leads to the immediate leakage of essential intracellular components (like ATP) and the loss of cellular homeostasis, leading to fungal cell non-viability.

Local Concentration Constraints on Efficacy

This domain addresses the physiological constraint on the full mechanism. While the enzyme inhibition (fungistatic effect) occurs at standard concentrations, the fungicidal mechanism is strictly dependent on achieving a high local concentration. Efficacy is thus inherently limited by the drug's ability to penetrate dense tissues, such as the keratin of thick nails, which may limit the extent of the fungicidal mechanism at the site of infection.

Dosage and Administration Information

How to Use Trosid (Tioconazole) — Administration Guidelines

Tioconazole, commonly marketed as Trosid, is an antifungal medication available in specific dosage forms for two approved routes of administration: topical for skin infections and intravaginal for vulvovaginal candidiasis. General instructions detail the necessary administration steps, frequency, and duration of use, which must be followed strictly.


Dosing and Administration Protocol

Dosage Form Route Standard Frequency Course Duration
Topical Cream To the skin Twice daily (e.g., morning and night) Varies: 2 to 4 weeks for most infections; up to 6 weeks for Athlete’s Foot
Vaginal Ointment (6.5%) Intravaginal Single-dose Single application

Procedural Instructions

Topical Application

Apply enough cream to cover the affected skin area and the surrounding skin. Gently rub the cream in. Unless otherwise directed, do not cover the treated area with an occlusive dressing (e.g., airtight bandage).

Intravaginal Application

Use the full contents of the applicator once, preferably just before bedtime. It is advised not to use tampons, douches, or other vaginal products during treatment. The vehicle in the vaginal ointment may damage latex or rubber products, meaning sexual intercourse relying on barrier contraception (e.g., condoms, diaphragms) is not recommended for 72 hours following administration.


Population-Specific Rules

For patients under 12 years of age, the safety and efficacy of Tioconazole have not been established in some contexts, and administration must be determined by a healthcare provider. The single-dose vaginal product is indicated for patients 12 years of age and older.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Tioconazole


Evidence for Use in Superficial Skin Infections (Dermatomycoses and Candidiasis)

Research for common fungal skin conditions, such as athlete’s foot and skin yeast infections, primarily consists of short-term Randomized Controlled Trials (RCTs) and comparative studies. These studies were generally studied for adult populations. Researchers focused on outcomes related to inflammatory states, monitoring how symptoms evolved, and whether clearance was reported from the skin.

Studies reported measurements of visible sign resolution and fungal elimination outcomes. Findings describe patterns observed over the immediate follow-up period, and research has explored the rates of clearance. A consistent research limitation is that follow-up durations were often limited; therefore, long-term outcomes are not well characterized.


Evidence for Use in Vulvovaginal Candidiasis

For vulvovaginal candidiasis, research examined the use of Tioconazole through RCTs, particularly those evaluating a single-dose regimen in non-pregnant adult females experiencing acute episodes. The primary objectives of these trials were to monitor symptom severity and to measure both mycological and clinical outcomes.

Data show patterns related to short-term mycological and clinical measures. However, evidence is limited when exploring the use of Tioconazole in managing Recurrent Vulvovaginal Candidiasis (RVVC), and data for certain subgroups with underlying conditions remain insufficient.


Evidence for Use in Fungal Nail Infections (Onychomycosis)

Research for fungal nail infections was evaluated in open-label trials and non-randomized studies, with outcomes monitored over long durations due to slow nail growth. Studies reporting patterns of limited or varied clinical clearance when the topical solution was used alone. Comparative evidence is currently lacking from recent, large-scale studies measuring this topical solution against alternatives.


Durability, Specific Groups, and Research Uncertainty

Most studies are relevant in trials assessing short-term or episodic symptom patterns, meaning long-term outcomes are not well characterized across the spectrum of uses. Findings relating to sustained mycological outcomes over many months are less characterized. Most clinical research examined healthy adult populations; results apply only to the populations studied. Data for pediatric or geriatric populations and those with comorbid conditions remain insufficient.

Studies contribute to the broader evidence landscape, but research highlights what is known and what is still uncertain. Certainty remains low regarding the measured outcomes of the topical nail solution in severe cases, and there is insufficient evidence to fully describe the sustained findings of any treatment over multiple years, particularly for recurrent or chronic fungal infections.

Frequently Asked Questions (FAQ)

Common questions about Trosid (FAQ)

Q: How long does it usually take to feel the effects of Trosid?

A: Studies and official information indicate that relief from symptoms like itching or irritation may begin within a few days after starting treatment. However, official guidelines recommend that the full prescribed course of treatment should be completed, even if symptoms improve quickly, to support the resolution of the fungal infection.

Q: What happens if I miss taking a dose of Trosid?

A: Official instructions describe applying the missed dose as soon as it is remembered. If it is nearly time for the next scheduled dose, official guidelines state that the missed dose is typically skipped to resume the regular schedule. Regulatory information advises against double applications at one time.

Q: Is it safe to drink alcohol in small amounts while on Trosid?

A: Official documents confirm that Trosid has negligible absorption into the bloodstream when applied topically or vaginally. Due to this low systemic exposure, there are no known drug interactions documented with alcohol.

Q: Is Trosid considered safe to use during pregnancy?

A: Official regulatory documents describe that use during pregnancy is conditional and requires discussion with a healthcare professional, as caution is advised. It is important to note that the topical solution (nail lacquer) formulation specifically carries a contraindication, meaning its use is generally prohibited during pregnancy.

Q: Why do official documents say Trosid is not for children under [Age]?

A: Trosid is generally indicated for patients 12 years of age and older. Use in younger children is not routinely recommended because official regulatory documents state that the safety and efficacy of the product have not been established in this pediatric population.

Q: How does the medicine know where to go in the body (mechanism of action simplified)?

A: The medication is designed for local action, meaning its purpose is to target the fungi only at the site of infection. When Trosid is applied to the skin or vagina, the active ingredient is absorbed only locally into the affected tissue, with negligible entry into the general bloodstream.

Q: Is a metallic taste in the mouth listed as a possible side effect of Trosid?

A: The official regulatory side effects listing does not include a metallic taste in the mouth as a commonly or uncommonly reported adverse effect of Trosid.

Q: Are there any foods that are strictly forbidden while taking Trosid?

A: Official regulatory labeling indicates that there are no known documented interactions with food.

Q: Do I need to take Trosid with food, or can I take it on an empty stomach?

A: Since Trosid is applied topically or intravaginally, its use is not dependent on what or when food is consumed. The medicine can be administered irrespective of mealtimes.

Q: Can Trosid interact with birth control pills?

A: Due to its negligible systemic absorption, Trosid is not associated with systemic drug-drug interactions. This means it is not expected to interfere with hormonal medications like oral contraceptives (birth control pills).

Q: What information is legally required to be included in the Trosid patient leaflet?

A: Regulatory agencies mandate that patient leaflets contain several key sections to inform the user. These include the drug's purpose, instructions for use, warnings/precautions, possible side effects, and storage/disposal instructions.

Q: Why is Trosid prescribed for [Condition A] when it's often associated with [Condition B]?

A: Trosid is officially classified as a broad-spectrum antifungal agent. This means the medicine is effective against a wide range of clinically recognized pathogenic fungi, which allows it to be used for different types of fungal infections across various parts of the body.

Q: Do I need to change my diet while taking Trosid?

A: Official regulatory documents indicate that there are no known requirements for changing one's diet while using Trosid, as it does not rely on dietary changes for its effectiveness or safety.

Q: Is there a known maximum duration for taking Trosid?

A: The duration of treatment is defined by the specific type of infection being treated, ranging from a single application up to 6 weeks for certain conditions. A general, lifetime maximum duration for the drug is not defined in regulatory labeling.

Q: What should I do if the expected effect of Trosid doesn't seem to happen?

A: Regulatory information advises that consultation with a healthcare provider is appropriate if symptoms do not start to improve within the expected timeframe, or if the symptoms worsen during treatment.

Q: Can Trosid be crushed or split if someone has trouble swallowing pills?

A: Trosid is formulated as a topical cream, solution, or vaginal ointment, and the product is not intended for oral ingestion. Regulatory documents provide no instructions for crushing or splitting the product for swallowing.

Q: Does the time of day matter when taking Trosid?

A: For the vaginal ointment formulation, administration is often specified as being preferably before bedtime to help optimize product retention. The topical cream is generally prescribed for use at a set frequency throughout the day, such as twice daily.

Q: What is the risk of dependence or withdrawal with Trosid?

A: The active ingredient, Tioconazole, is not classified as a narcotic, controlled substance, or a drug with known potential for dependence or withdrawal effects.

Q: Is the use of Trosid connected to long-term health issues?

A: There are no specific long-term health issues known or listed in regulatory warnings for the product. Research documents note that long-term outcomes are not extensively characterized beyond the immediate follow-up period.

Q: What conditions must be met for a doctor to consider me eligible for Trosid?

A: Regulatory agencies specify that the medicine is used to treat clinically diagnosed superficial fungal infections. This means a healthcare provider would first confirm the presence of an infection caused by susceptible organisms, such as Tinea or Candida species.

Q: How does Trosid work differently than a vaccine, since it deals with [Condition category]?

A: Trosid is an antifungal treatment that works by physically interfering with the structure of existing fungal cells to stop their growth. In contrast, a vaccine is a preventative product that stimulates the body’s own immune system to defend against future infections.

Q: Can I stop taking Trosid immediately if I feel better?

A: Official instructions describe using the medicine for the full prescribed duration, even if symptoms improve quickly. This consistency is important to support the resolution of the infection and minimize the risk of recurrence.

Q: Are there any special patient monitoring requirements when starting Trosid?

A: Regulatory documents do not require routine laboratory tests or specialized patient monitoring beyond following general treatment guidelines. This is due to the drug’s local action and negligible absorption into the bloodstream.

Q: Can people with lactose intolerance take tablets containing Trosid?

A: Trosid is supplied as a cream, solution, or ointment, not a typical oral tablet. Regulatory labeling for these specific topical and vaginal formulations does not list lactose as an an inactive ingredient.

Q: What is the difference between the active ingredient and the inactive ingredients in Trosid?

A: The active ingredient (Tioconazole) is the substance intended to have a therapeutic effect against the infection. Inactive ingredients are all other components added to aid in formulation, stability, and proper application but do not directly treat the infection.

Q: How does the body get rid of Trosid after it has been used?

A: Due to its local application, only a small amount of Trosid is absorbed into the body. This small systemic portion is then primarily eliminated via urine and feces, typically within 72 hours of administration.

Q: Is Trosid known to cause changes in sleep patterns?

A: Official regulatory side effects listings do not include changes in sleep patterns, such as insomnia or drowsiness, as a common, uncommon, or unknown reported adverse effect.

Q: What should I do if I accidentally take two doses of Trosid?

A: Official information indicates that a local overdose from topical or vaginal use is generally not expected to cause serious systemic effects due to the negligible absorption into the bloodstream.

Q: Is there a particular organ in the body that Trosid targets most directly?

A: Trosid is applied to the skin or vagina for a local effect. The medication’s action is highly localized, meaning its target is the fungal cell within the tissue layer of the infection site, not a particular internal organ.

Q: Are there any specific medical conditions that absolutely prohibit the use of Trosid?

A: Regulatory documents list a known hypersensitivity (allergy) to Tioconazole or other imidazole antifungals as an absolute prohibition (contraindication). Additionally, the use of the nail lacquer formulation in pregnancy is prohibited.

How should Trosid be stored and disposed of?

How to Store and Dispose of Trosid: Official Regulatory Information

The official labeled instructions for storing and disposing of Trosid (Tioconazole) are based on regulatory requirements to maintain product stability and ensure environmental safety. These statements strictly define storage constraints and disposal rules.

Storage Requirements

Classification Official Statement
Temperature Store at room temperature.
Protection Keep away from heat, sparks, and flames.
Packaging Store in properly labeled containers.

Disposal Instructions

Disposal must be conducted in accordance with all applicable local and national laws and regulations. Regulatory documents state that this substance is harmful to aquatic organisms and may cause long-term adverse effects in the aquatic environment. Therefore, releases to the environment should be avoided, and appropriate containment must be used.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Trosid found in:

A-Z Index: